



VÉTOQUINOL REGISTERS ITS INJECTABLE MARBOCYL® 2% AND MARBOCYL® 10% ANTIBIOTICS IN JAPAN

November 16, 2010 (Lure, France) – Vétoquinol has just obtained Marketing Authorisation (MA) from Japanese drug authorities for its Marbocyl® 2% and Marbocyl® 10% antibiotics for livestock.

The authorisation to market this 'flagship' antibiotic in one of the world's most heavily regulated markets demonstrates the strength of Vétoquinol's research and development teams, capping several years of scientific work in partnership with the research laboratory of Meiji Seika, one of the leaders in the Japanese pharmaceutical market.

The launch of this anti-infective agent for cattle and pigs will deliver significant progress in the treatment of respiratory diseases. Marbocyl® 2% and Marbocyl® 10% are two versions of the Marbocyl product line developed by Vétoquinol's research. This line of antibiotics, a leader in the treatment of infections, consists of six products – 10%, S and 2% injectable solutions, bolus, lyophilisate, and tablets – intended for different animal species.

This marketing approval strengthens the position of the Vétoquinol Group – which has been selling in the Japanese market through distributors for the past seven years – in a key animal health market. (Japan is the world's ninth largest animal health market).

"We are very satisfied to have obtained marketing approval for Marbocyl® in Japan, once again demonstrating the excellence of this product line developed by our research," stated Matthieu Frechin, CEO of Vétoquinol. *"We have high hopes for this market, and we intend to intensify our local partnerships".* Already operating in South Korea and India, Vétoquinol is actively pursuing sales growth in Asia-Pacific, one of the most promising regions for the animal health market.

About Vétoquinol

Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group, dedicated exclusively to animal health, is the 10th largest animal healthcare laboratory in the world. More than 80% of its revenues are generated outside France.

Vétoquinol's business includes research and development, production and marketing of medicinal and non-medicinal products. Vétoquinol has positioned itself in the curative sector and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation and cardiology/nephrology.

The Group currently distributes its products in more than one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 23 countries and a network of 140 distribution partners. The company has more than 1,550 employees worldwide.

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL

Finance department

Marie-Josée AUBRY-ROTA

Tel.: +33 (0)3 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor relations

Emmanuel DOVERGNE

Tel.: +33 (0)1 56 43 44 63

emmanuel.dovergne@keima.fr

Media relations

Sibylle DESCAMPS

Tel.: +33 (0)1 56 43 44 72

sibylle.descamps@keima.fr